PF-04634817 Renal Impairment Study

• Drug: PF-04634817
  
  Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
• Drug: PF-04634817
  
  Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
• Drug: PF-04634817
  
  Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
• Drug: PF-04634817
  
  Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)

• Experimental: Healthy Volunteers
  
  Intervention: Drug: PF-04634817
• Experimental: Mild Renal Impairment
  
  Intervention: Drug: PF-04634817
• Experimental: Moderate renal impairment
  
  Intervention: Drug: PF-04634817
• Experimental: Severe renal impairment
  
  Intervention: Drug: PF-04634817

Inclusion Criteria:

• Male or female (non child bearing potential aged 18-75 years
• Documented renal impairment (mild, moderate or severe using Cockcroft-Gault equation) or matched healthy volunteers (age, weight and gender)

Exclusion Criteria:

• Subjects with acute renal failure
• Subjects receiving, or likely to receive, CYP450 3A4 inhibitors
• Abnormal ECG at screening